Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death
Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of these viruses that cause lethal hemorrhagic fever (HF). We developed a quadrivalent formulation of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus glycoproteins and that also contains a rVSV vector expressing the glycoprotein of a lineage IV strain of LASV. Cynomolgus macaques were vaccinated twice with the quadrivalent formulation, followed by challenge 28 days after the boost vaccination with each of the 3 corresponding filoviruses (Ebola, Sudan, Marburg) or a heterologous contemporary lineage II strain of LASV. Serum IgG and neutralizing antibody responses specific for all 4 glycoproteins were detected in all vaccinated animals. A modest and balanced cell-mediated immune response specific for the glycoproteins was also detected in most of the vaccinated macaques. Regardless of the level of total glycoprotein-specific immune response detected after vaccination, all immunized animals were protected from disease and death following lethal challenges. These findings indicate that vaccination with attenuated rVSV vectors each expressing a single HF virus glycoprotein may provide protection against those filoviruses and LASV most commonly responsible for outbreaks of severe HF in Africa.
US drugmaker Johnson&Johnson says the vaccine could be available for use by early 2021 if proven safe, effective. In the next phase J&J will enroll up to 60,000 volunteers across three continents and study safety and efficacy of a single vaccine dose.
Johnson&Johnson has advanced its one-shot COVID-19 vaccine into phase 3 testing. The National Institute of Allergy and Infectious Diseases describes this as the fourth candidate to reach this stage.Medscape Medical News
Unlike some of its competitors, Johnson&Johnson ’s vaccine does not need to be frozen and may require just one shot instead of two.
Dr. Anthony S. Fauci and three other top U.S. health officials steering the government ’s virus response told senators that they would take a vaccine approved by the F.D.A. Johnson&Johnson announced that it plans to enroll 60,000 people in its Phase 3 vaccine trial.
In this study, we compared the immunogenicity and protective efficacy of CMFO subunit vaccines against primary progressive TB in two different adjuvant systems: the MTO oil-in-water (O/W) emulsion composed of monophosphoryl lipid A (MPL), trehalose-6,60-dibehenate (TDB), and oil in water emulsion MF59 and the DMT liposome containing dimethyldioctadecylammonium bromide (DDA), monophosphoryl lipid A (MPL), and trehalose-6,60-dibehenate (TDB). Our results demonstrated that the DMT-adjuvanted CMFO could confer more significant protection against M. tuberculosis infection than the CMFO/MTO did in mice. In particular, the adjuva...
Publication date: Available online 21 September 2020Source: The LancetAuthor(s): Enrico Bucci, Konstantin Andreev, Anders Björkman, Raffaele Adolfo Calogero, Ernesto Carafoli, Piero Carninci, Paola Castagnoli, Andrea Cossarizza, Cristina Mussini, Philippe Guerin, Brian Lipworth, Gianluca Sbardella, Teresa Stocki, Loretta Tuosto, Christoffer van Tulleken, Antonella Viola
Publication date: Available online 21 September 2020Source: The LancetAuthor(s): Denis Y Logunov, Inna V Dolzhikova, Amir I Tukhvatullin, Dmitry V Shcheblyakov
Publication date: Available online 21 September 2020Source: The LancetAuthor(s): Malik Peiris, Gabriel M Leung
Dr. Anthony Fauci says it wouldn’t be smart for college administrators to send students home if there’s an outbreak on campus
Publication date: October 2020Source: American Journal of Infection Control, Volume 48, Issue 10Author(s): Justin J. Kim, KC Coffey, Daniel J. Morgan, Mary-Claire Roghmann